EUCTR2021-002821-32-ES进行中（未招募）1 期
The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes. - The FENDEEP Study
eurologia Aplicada, SLP0 个研究点目标入组 20 人开始时间: 2021年12月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •General inclusion criteria:
- •- Age between 2 and 35 years (both included).
- •- Diagnosis of epilepsy associated with some degree of intellectual disability, starting before 11 years of age.
- •- All patients will have a phenotype consistent with their genetic, electroclinical or neuroimaging diagnosis.
- •Specific inclusion criteria per group:
- •Non-controlled epilepsy after failing at least 3 antiseizure medications, with a minimum of 4 countable seizures with motor semiology per month during the baseline period of 3 months.
- •- Group 1A: Patients with genetic testing showing a pathogenic or likely pathogenic variant in main synaptopathy genes (SYNGAP1 and STXBP1).
- •- Group 1B: Patients with genetic testing showing a pathogenic or likely pathogenic inverted duplication of chromosome 15 [inv-dup (15)].
- •- Group 1C: Patients with neuroimaging showing multifocal or bilateral malformations of cortical development.
- •Electroclinical diagnosis of Continuous Spikes and Waves during Sleep (CSWS) syndrome, with baseline video-EEG monitoring showing epileptiform activity occupying at least 50% of slow sleep tracing, after failing at least 3 antiseizure medications.
- •Additional inclusion criteria:
- •In addition, all subjects must meet all of the following inclusion criteria to be enrolled into the study:
- •- Subject is male or non-pregnant, non-lactating female. Female subjects of childbearing potential must not be pregnant or breast-feeding. Female subjects of childbearing potential must have a negative urine or serum pregnancy test at screening and during the study.
- •- Receiving at least 1 concomitant antiseizure medications (ASMs) and up to 4 concomitant ASMs, inclusive. KD and VNS are permitted but do not count towards the total number of ASMs. Rescue medications for seizures are not counted towards the total number of ASMs.
- •- All medications or interventions for epilepsy (including ketogenic diet and vagal nerve stimulation) must be stable for at least 4 weeks prior to screening and are expected to remain stable throughout the study.
- •- Subject has been informed of the nature of the study and informed consent has been obtained from the legally responsible parent/guardian.
- •- Subject has provided assent in accordance with Institutional Review Board (IRB)/Ethics Committee requirements, if capable.
- •- Subject’s parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who meet any of the following exclusion criteria will not be enrolled into the study:
- •- Subject has a known hypersensitivity to fenfluramine or any of the excipients in the study medication.
- •- Subject has only non-motor seizures (such as absences), for group 1.
- •- Subject has pulmonary arterial hypertension.
- •- Subject has current or past history of cardiovascular or cerebrovascular disease.
- •- Subject has current or recent history of Anorexia Nervosa, bulimia, or depression within the prior year that required medical treatment or psychological treatment for a duration greater than 1 month.
- •- Subject has a current or past history of glaucoma.
- •- Subject has moderate or severe renal or hepatic impairment.
- •- Subject is receiving concomitant therapy with any of the following: centrally-acting anorectic agents; monoamine-oxidase inhibitors; any centrally-acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; other centrally-acting noradrenergic agonists.
- •- Subject is currently receiving an investigational product.
- •- Subject has participated in another clinical trial within the past 30 days (calculated from that study’s last scheduled visit).
- •- Subject is at imminent risk of self-harm or harm to others.
- •- Subject is unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
- •- Subject is institutionalized in a general nursing home (i.e., in a facility that does not provide skilled epilepsy care).
- •- Subject does not have a reliable caregiver who can provide seizure diary information throughout the study.
- •- Subject has a severe clinically significant condition.
研究者
相似试验
招募中
4 期
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic OutcomesSYNGAP1 EncephalopathyRefractory EpilepsySTXBP1 Encephalopathy With EpilepsyInv Dup(15) EncephalopathyMultifocal or Bilateral Malformations of Cortical DevelopmentContinuous Spike and Waves During Slow SleepNCT05232630Hospital Ruber Internacional20
进行中（未招募）
不适用
A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ciclosporin - PICCOLO: Panitumumab, Irinotecan & Ciclosporin in Colorectal cancer therapyEUCTR2005-003492-20-GBniversity of Leeds1,324
已完成
3 期
Evaluation of efficacy and safety of Fenofibrate in COVID-19 patientsIRCT20220612055149N1Artesh University of Medical Sciences70
已完成
2 期
Effects of fluoride and laser on streptococcus mutansIRCT2017061817756N20Vice-Chancellery for Research and Technology of Birjand University of Medical Sciences36
招募中
不适用
A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) according to the approved label.relapsed and/or refractory multiple myelomaC90.0Multiple myelomaDRKS00033264Oncopeptides AB100